$IRON

Disc Medicine ($IRON) shares tumbled 22% following FDA rejection of its bitopertin program. Law firm investigates potential securities violations and shareholder losses.

Rosen Law Firm solicits ODDITY Tech investors with $100k+ losses for securities class action over alleged false statements about business impact from advertising algorithm changes.

FDA rejected Disc Medicine's bitopertin drug application on February 13, 2026, triggering a 22% stock plunge. The Rosen Law Firm investigates potential securities claims for affected shareholders.

Polycythemia vera market expected to expand 8.9% CAGR through 2036 from $2B base as nine pharma companies advance novel therapies, with rusfertide entering first.

Disc Medicine to present Phase 2 DISC-0974 data showing unprecedented anemia response rates in myelofibrosis at ASCO 2026, potentially reshaping treatment landscape.

Disc Medicine ($IRON) shares fell 22% after FDA rejected its bitopertin drug application, prompting class action investigation into securities claims.

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.

Disc Medicine ($IRON) stock fell 22% after FDA rejected bitopertin program, triggering class action lawsuit investigation by Rosen Law Firm.

Disc Medicine faces securities probe after FDA rejects bitopertin drug; stock slides 22% on February 13, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

FDA rejects Disc Medicine's bitopertin drug, triggering 22% stock decline and securities investigation into potential investor losses.

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.